Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the phase 3 VISIONARY trial shows a significant reduction in proteinuria with a 50% decrease in the uPCR-24h ratio compared to placebo, which indicates a moderate benefit over current care. However, the FDA label notes that long-term clinical benefit has not been established, which limits the strength of the evidence.
Cost effectiveness
The ICER report indicates a very high ICER of $894,000 per QALY gained, which is well above typical thresholds for cost-effectiveness, suggesting poor value for the treatment.
Quality of life
No validated HRQoL outcomes were reported in the pivotal trials or the FDA label, indicating a complete absence of evidence regarding the impact of sibeprenlimab on quality of life.
Supporting Domains
Safety and Adverse Effects
The safety profile shows that adverse events were mostly mild to moderate, with a high percentage of patients experiencing adverse events but no significant safety concerns compared to placebo. Serious adverse events were low, indicating good tolerability.
Comparator Selection
The trials used placebo as a comparator, which is acceptable but does not provide a direct comparison to other active treatments for IgAN, limiting the robustness of the evidence.
Patient Population and Subgroups
The trial population is broadly representative of the intended patient population with a diverse demographic and relevant clinical characteristics, although subgroup analyses were limited.
Care Pathway Integration
The treatment can be integrated into existing care pathways with minimal adjustments, as it is administered subcutaneously every four weeks and does not require significant changes to current practices.
Resource Use and Cost Implications
The annual net price of $292,500 raises concerns about the affordability and budget impact, indicating a high resource burden that may require restrictions.
Evidence Quality and Robustness
The evidence is based on rigorous phase 2 and phase 3 trials with clear endpoints and statistical significance, although the long-term outcomes remain uncertain.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term benefits of the treatment, as indicated by the FDA’s accelerated approval status and the need for confirmatory evidence.
